MIT Technology Review June 6, 2017
Dan Rhodes, Strata's co-founder and CEO, comments on the need to provide cancer patients broad access to tumor profiling to identify those who will benefit from targeted therapy drugs. Read the article here.
MedCity News May 24, 2017
Dr. Scott Tomlins, Strata's co-founder and Laboratory Director, comments on the accelerated approval of Keytruda for MSI-H and dMMR cancers and the opportunity to accelerate the approval of additional precision therapies in biomarker-defined patient populations. At Strata Oncology, we believe that by institutionalizing tumor sequencing and clinical trial participation across a large network of hospitals, we can help usher in the next wave of biomarker-guided precision medicine approvals. Read the article here.
Ann Arbor, MI, May 23, 2017
Birmingham, AL, May 19, 2017
Ann Arbor, MI, February 6, 2017
CLOVIS ONCOLOGY AND STRATA ONCOLOGY ANNOUNCE COLLABORATION TO ACCELERATE ENROLLMENT IN RUCAPARIB PROSTATE CANCER DEVELOPMENT PROGRAM
Boulder, CO & Ann Arbor, MI, February 1, 2017
Ann Arbor, MI, December 16, 2016
STRATA ONCOLOGY COMPLETES SERIES A FINANCING AND SIGNS STRATEGIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC
Ann Arbor, MI, June 1, 2016